Doç. Dr. TOLGA KÖŞECİ

Yayın Ağı

Makaleler 37

1. Impact of adjuvant endocrine therapy on disease-free survival in early triple-positive breast cancer: a multicenter retrospective cohort study of the Turkish oncology group

Seyyar M., Şancı P. C., Doğan A., Biter S., KÖŞECİ T., Balçık O. Y., et al.

BMC Cancer , cilt.26, sa.1, 2026 (SCI-Expanded, Scopus)

2. The prognostic significance of early changes in the lung immune prognostic index in patients treated with immunotherapy for advanced-stage lung cancer

Cengiz M., BOZKURT O., NURANSOY CENGİZ A., İNANÇ M., ÖZKAN M., Mutlu Ozkan E., et al.

Discover Oncology , cilt.17, sa.1, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

3. Flow-dependent drug response of breast Cancer organoids in an organ-on-Chip platform

Kocamaz E., Aslan D., ÖZBOLAT V., KÖŞECİ T., CANPOLAT Ç.

Microchemical Journal , cilt.229, 2026 (SCI-Expanded, Scopus)

4. Claudin 18.2 Expression in Cholangiocarcinoma: Clinicopathological Heterogeneity, Prognostic Significance, and Impact of Positivity Thresholds

TOYRAN T., Eren Ates K., PİŞKİN F. C., KÖŞECİ T., Asoglu H., ARSLAN Y. K., et al.

Journal of Clinical Medicine , cilt.15, sa.17, 2026 (SCI-Expanded, Scopus)

5. Is There a Tumor Proportion Score Threshold at Which Tumor-Cell PD-L1 Adds Prognostic Information Beyond the International Prognostic Index in Large B-Cell Lymphoma?

Kidi M. M., Atas Ipek S., Yaslikaya S., BÜYÜKŞİMŞEK M., Turker M., Aydinalp Camadan Y., et al.

Diagnostics , cilt.16, sa.18, 2026 (SCI-Expanded, Scopus)

6. Association of p16 Loss and EZH2 Overexpression with Clinicopathological Characteristics and Prognosis in Gastrointestinal Stromal Tumors

TOYRAN T., ATEŞ K. E., KÖŞECİ T., TOPAL U., PARSAK C. K., ARSLAN Y. K., et al.

Çukurova Anestezi ve Cerrahi Bilimler Dergisi , cilt.9, sa.3, ss.870-884, 2026 (TRDizin)

7. Prognostic Value of the Modified Glasgow Prognostic Score in Patients with Metastatic Renal Cell Carcinoma Receiving Nivolumab as Second-Line Therapy: A Multicentre Retrospective Cohort Study

Biter S., BAYRAM E., KÖŞECİ T., İçli M. C., Arslan A. M., Özalp F. R., et al.

Medicina (Kaunas, Lithuania) , cilt.62, sa.9, 2026 (SCI-Expanded, Scopus)

8. Clinicopathological Features, Tumor Localization and Treatment Outcomes in Paraganglioma: A Single-Center Medical Oncology Cohort

Asoglu H., Asarkaya E., Aykut A., Cavusoglu G. D., Aydinalp Camadan Y., Kolsuz Turker I., et al.

Diagnostics , cilt.16, sa.16, 2026 (SCI-Expanded, Scopus)

9. Quantitative Immunohistochemical Landscapes and Chemoimmunotherapy Outcomes of ASCL1, NEUROD1, POU2F3, and YAP1 in Pure Small-Cell Lung Cancer: A Pilot Study

Aydinalp Camadan Y., Demir Ispir A., BAĞIR KILIÇ E., METE B., Asoglu H., Turker M., et al.

Journal of Clinical Medicine , cilt.15, sa.16, 2026 (SCI-Expanded, Scopus)

10. First-Line Palbociclib/Letrozole Versus Ribociclib/Letrozole in Postmenopausal HR-Positive/HER2-Negative Metastatic Breast Cancer: A Retrospective Real-World Study and an Exploratory Composite Clinical-Inflammatory Risk Score

TOHUMCUOĞLU M., Yetişir A. E., Cinkara Z. U., Türker M., Düşgün A., Mirili C., et al.

Medicina (Lithuania) , cilt.62, sa.8, 2026 (SCI-Expanded, Scopus)

11. Real-World Outcomes and Prognostic Factors in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Multicenter Study

Atas Ipek S., Yaslikaya S., KARA İ. O., KÖŞECİ T., BAYRAM E., Asarkaya E., et al.

Journal of Clinical Medicine , cilt.15, sa.13, 2026 (SCI-Expanded, Scopus)

12. Enzalutamide Versus Abiraterone After Docetaxel in Metastatic Castration-Resistant Prostate Cancer: Real-World Outcomes and Exploratory Prognostic Stratification

Tohumcuoğlu M., KÖŞECİ T., Düşgün A., Yetişir A. E., Mirili C., METE B., et al.

Journal of Clinical Medicine , cilt.15, sa.12, 2026 (SCI-Expanded, Scopus)

13. Brigatinib-associated autoimmune hepatitis: A case report

Buyuksimsek M., Ogul A., Yetisir A. E., Duman B. B., Tohumcuoglu M., Cil T., et al.

Journal of Oncology Pharmacy Practice , cilt.32, sa.4, ss.754-756, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

14. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., SALİ M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.

Current Oncology , cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)

15. Impact of Anatomical Localization on Systemic Inflammatory Markers and Immune Checkpoint CD47 in Desmoid Tumors

Yaslikaya S., Atas Ipek S., BALIKÇI ÇİÇEK İ., Asarkaya E., Asoglu H., Ergozoglu M. A., et al.

Journal of Clinical Medicine , cilt.15, sa.11, 2026 (SCI-Expanded, Scopus)

16. Dose-Adjusted EPOCH-R in Aggressive B-Cell Lymphomas: Efficacy, Molecular Prognostic Factors, and Real-World Outcomes from a Multicenter Turkish Cohort—A Turkish Oncology Group (TOG) Study

Kidi M. M., Asoglu H., Soysal M., KÖŞECİ T., KARA İ. O., ŞAHİN B., et al.

Medicina (Lithuania) , cilt.62, sa.6, 2026 (SCI-Expanded, Scopus)

17. The significance of MDM-2 positivity in stage 4 non-small cell lung cancer.

Kara O., ataş Ipek Ş., Ã§alkan GÃ¼ndÃ¼z F., GÜMÜRDÜLÜ D., BAĞIR KILIÇ E., BAYRAM E., et al.

Journal of Clinical Oncology , cilt.44, sa.16, 2026 (SCI-Expanded, Scopus)

18. First-Line Treatment After Perioperative FLOT in Recurrent Gastric and Gastroesophageal Junction Cancer: A Turkish Oncology Group (TOG) Multicenter Real-World Analysis

Seyyar M., Can Şancı P., SAKİN A., Bayramgil A., Dülgar Kaya Ö., SÜNGER E., et al.

Medicina (Lithuania) , cilt.62, sa.5, 2026 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

19. Questioning the association between prophylactic antibiotics and improved prognosis in gastric cancer immunotherapy

Ilhan Y., KÖŞECİ T.

Oncologist , cilt.31, sa.4, 2026 (SCI-Expanded, Scopus)

20. Real-World Outcomes of Irinotecan–Bevacizumab Therapy in Recurrent Brain Tumors: A Retrospective Cohort Study

Seyyar M., Şancı P. C., kalem a., METE B., KÖŞECİ T., Karakayalı A., et al.

Çukurova Anestezi ve Cerrahi Bilimler Dergisi , cilt.9, sa.1, ss.132-137, 2026 (TRDizin)

21. Impact of renin–angiotensin system inhibitors on the clinical outcomes of nivolumab therapy in metastatic non–small cell lung cancer

Mutlu Ozkan E., Karadağ I., Sahın E., NURANSOY CENGİZ A., Cengız M., Can Guven D., et al.

Expert Review of Anticancer Therapy , cilt.26, sa.7, ss.929-936, 2026 (SCI-Expanded, Scopus)

22. Prognostic Significance of C-PLAN Index in Patients Treated with Immunotherapy for Non-Small-Cell Lung Cancer

NURANSOY CENGİZ A., BOZKURT O., Cengiz M., ÖZKAN M., İNANÇ M., KEFELİ U., et al.

Journal of Clinical Medicine , cilt.15, sa.2, 2026 (SCI-Expanded, Scopus)

23. HALP-H Index as a Prognostic Biomarker for Predicting Pathological Complete Response in Early-Stage HER2-Positive Breast Cancer—A Multicenter Retrospective Cohort Study

Seyyar M., Şancı P. C., KÖŞECİ T., Karakayalı A., Akdağ M. Ö., Temi Y. B., et al.

Journal of Clinical Medicine , cilt.14, sa.13, 2025 (SCI-Expanded, Scopus)

24. Evaluation of the efficacy of regorafenib treatment by location and RAS mutation in metastatic colon cancer

Ata S., Gülmez A., KÖŞECİ T., Özalp Ö., Çil T., Duman B. B.

Medicine (United States) , cilt.104, sa.26, 2025 (SCI-Expanded, Scopus) Sürdürülebilir Kalkınma

25. The prognostic value of halp score in predicting the efficacy of nivolumab treatment in metastatic malignant melanoma patients: A real-life, retrospective, single center analysis

Ata S., KÖŞECİ T., Benli B. A., Bayhan A. Z., Kesen O., Solmaz A. A., et al.

Medicine (United States) , cilt.104, sa.18, 2025 (SCI-Expanded, Scopus)

26. Nonsteroidal Antiinflamatuvar İlaçların Kemopreventif Etkileri

Ölmez S., Köşeci T., Kozanoğlu M. E.

Sağlık bilimlerinde değer (Online) , cilt.15, sa.2, ss.315-320, 2025 (TRDizin)

27. Prognostic Significance of the Combined Albumin-To-Alkaline Phosphatase Ratio (AAPR) and Haemoglobin–Albumin–Lymphocyte–Platelet (HALP) Score in Patients with Metastatic Renal Cell Carcinoma Treated by Targeted Therapy: A New Prognostic Combined Risk Scoring

KÖŞECİ T., Seyyar M., Kıdı M. M., Biter S., Eser K., KEFELİ U., et al.

Journal of Clinical Medicine , cilt.14, sa.5, 2025 (SCI-Expanded, Scopus)

28. Regorafenib Treatment for Recurrent Glioblastoma Beyond Bevacizumab-Based Therapy: A Large, Multicenter, Real-Life Study

Tünbekici S., Yuksel H. c., Acar C., Sahin G., Orman S., Majidova N., et al.

Cancers , cilt.17, sa.1, 2025 (SCI-Expanded, Scopus)

29. Efficacy of everolimus plus hormonal treatment after cyclin-dependent kinase inhibitor; real-life experience, A TOG study

Beypınar İ., Demir H., YASLIKAYA Ş., KÖŞECİ T., Demir B., Çolak G., et al.

Breast Cancer Research and Treatment , cilt.208, sa.3, ss.597-604, 2024 (SCI-Expanded, Scopus)

30. Exploring the Impact of Cytogenetic Abnormalities on Treatment Responses and Survival Outcomes in Multiple Myeloma: A Single-Centre Experience of 13 Years of Follow-Up

Bayram E., Köşeci T., Mete B., Toyran T., Kara İ. O.

BIOMEDICINES , cilt.12, sa.5, ss.1-13, 2024 (SCI-Expanded, Scopus)

31. Diagnostic Significance of Pre-Treatment Prognostic Nutritional Index, Platelet/Albumin Ratio and Red Cell Distribution Width in Patients with Differentiated Glioblastoma from Brain Metastasis

OLGUN P., KÖŞECİ T., BAYRAM E., HAKSÖYLER V., BOZKURT DUMAN B., ÇİL T.

Eurasian Journal of Medical Investigation , cilt.7, sa.4, ss.426-432, 2023 (TRDizin)

32. Importance of Prognostic Nutritional Index in Patients with Metastatic Breast Cancer Treated with Trastuzumab Emtansine

KÖŞECİ T., BULUT G., ATA S., BAYRAM E., ÇİL T., ESER K.

Eurasian Journal of Medical Investigation , cilt.6, sa.4, ss.484-490, 2022 (TRDizin)

33. Erişkin Dönemin Nadir Görülen Beyin Tümörü: Medulloblastom Tanılı 28 Hastanın Demografik Özellikleri

KÖŞECİ T., ATA S., SEYYAR M., OLGUN P., BAYRAM E., ESER K., et al.

Çukurova Anestezi ve Cerrahi Bilimler Dergisi , cilt.5, sa.2, ss.235-240, 2022 (TRDizin)

34. Clinicopathological Features of Gastroenteropancreatic Neuroendocrine Tumors: A Retrospective Evaluation of 149 Cases

KÖŞECİ T., OLGUN P., ATA S., SEYYAR M., TAŞ Z. A., BAYRAM E., et al.

Eurasian Journal of Medical Investigation , cilt.6, sa.2, ss.222-226, 2022 (TRDizin)

35. Prognostic importance of peripheral blood parameters in HER-2 positive metastatic breast cancer treated by pertuzumab, trastuzumab and docetaxel

KÖŞECİ T., OLGUN P., ATA S., BAYRAM E., SUNGUR M. A., ESER K., et al.

Medical Science and Discovery , cilt.8, sa.12, ss.730-734, 2021 (Hakemli Dergi) Sürdürülebilir Kalkınma

36. Effectiveness and Reliability of Scalp Cooling in Preventing Hair Loss Caused by Chemotherapy

HAKSÖYLER V., KÖŞECİ T., OLGUN P., BAYRAM E., ÇAPARLAR M. A.

Kocaeli Tıp Dergisi , cilt.10, sa.2, ss.133-140, 2021 (TRDizin)

37. Investigation of the change in the biological structure of the tumor in metastatic breast cancer

HAKSÖYLER V., KÖŞECİ T., ÇİL T., BOZKURT DUMAN B., OLGUN P., BAYRAM E., et al.

Medical Science and Discovery , cilt.8, sa.3, ss.171-174, 2021 (Hakemli Dergi)

Hakemli Bilimsel Toplantılarda Yayımlanmış Bildiriler 4

1. Management of Hepatocellular Carcinoma in a Patient with Glycogen Storage Disease Type 1a.

BULUT F. D., BALLI H. T., ŞAHİN B., KOR D., BURGAÇ E., KAPLAN İ., et al.

Society for the Study of Inborn Errors of Metabolism Annual Symposium, Sydney, Avustralya, 30 Ağustos - 02 Eylül 2022, (Özet Bildiri)

2. MANTLE HÜCRELİ LENFOMALI HASTADA SKUAMÖZ HÜCRELİ AKCİĞER KANSERİ BİRLİKTELİĞİ

BAYRAM E., KÖŞECİ T., ADAMHASAN F., GÜMÜRDÜLÜ D., BOZKURT DUMAN B., ÇİL T.

6. TÜRK TIBBI ONKOLOJİ KONGRESİ, Türkiye, 23 Mart 2016, (Özet Bildiri)

3. PROSTAT BEZİNİN PRİMER DİFFÜZ BÜYÜK B HÜCRELİ LENFOMASI:NADİR GÖRÜLEN BİR OLGU

KÖŞECİ T., HAKSÖYLER V., BAYRAM E., POLAT KELLE A., BOZKURT DUMAN B., ÇİL T.

6. TÜRK TIBBI ONKOLOJİ KONGRESİ, Türkiye, 23 Mart 2016, (Özet Bildiri)

4. MULTİPLE KARACİĞER METASTAZINA BAĞLI BİLİRUBİN YÜKSEKLİĞİ OLAN KOLOREKTAL KANSERLİ HASTADA 5 FLUOROURASİL DOZ REDUKSİYONU İLE ELDE EDİLEN TEDAVİ ETKİNLİĞİ.OLGU SUNUMU

HAKSÖYLER V., KÖŞECİ T., BAYRAM E., POLAT KELLE A., BOZKURT DUMAN B., ÇİL T.

6.TÜRK TIBBİ ONKOLOJİ KONGRESİ, Antalya, Türkiye, 23 Mart 2016, (Özet Bildiri)

Yayınlar & Eserler